SANGUI BIOTECH INT COM USD0.001 (SGBI)

0.02
OTC Markets
Prev Close 0.02
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.04
Exchange OTC Markets
Shares Outstanding 181.76B
Market Cap 4.00M
Div & Yield N.A. (N.A)

TV Station Owners, FCC Hit With Setback as Court Stays Discount Rule

Tegna and Gray shares were falling after the Republican-controlled FCC was dealt a setback by a federal appeals court.

Jim Cramer on Sinclair's Purchase of Tribune: Local TV Is Still Worth a Great Deal

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer was fond of Sinclair's SGBI purchase of Tribune TRCO and said that local television is "still worth a great deal."

Tribune Leads Media Stocks' Surge in Trump's First 100 Days, as Fox Trails the Pack

Media stocks have outperformed the market since the inauguration of Donald Trump, with TV station owners led by Tribune Media pacing the sector.

For Fox News, Bill O'Reilly's Ouster Comes at an Extremely Tricky Time

The network is sure to put on a brave face as it enters broadcasts without its top-rated host, but its dominance over cable TV news may never be the same.

Sinclair Buying Tribune? Not So Fast With All This TV Station Group Merger Talk

Sinclair is eager to buy other station groups, and Tribune Media may be a seller. But any deal involving the country's largest TV station owners will require FCC rule changes.

Tribune Media Rising on Deal Speculation Despite Obstacles to Sale

Tribune Media stock continued a monthlong climb on Monday amid speculation that the WGN America owner eventually could win regulatory approval for a sale of the Chicago-based TV station group.

TV Companies Stand to Win if Trump Removes Media Ownership Limits

Sinclair Broadcasting, Tribune Media and Tegna could be big winners if a Trump administration moved to loosen laws limiting the concentration of media ownership.

Sangui BioTech: British National Health Service NHS Granted Wound Spray Granulox Reimbursement

The SastoMed GmbH has announced that the British National Health Service (NHS) has taken the wound spray Granulox licensed by Sangui to SastoMed GmbH on the list of reimbursable products under a discrete category (NHS Drug...

Sangui BioTech: Third Quarter Report

In the first nine months of fiscal year 2016 (to 31/03/2016) Sangui BioTech International Inc.

Sangui BioTech International Publishes Preliminary Figures For First Half Year

According to preliminary unaudited figures, Sangui BioTech International Inc.

Media General Merger Gives Better Digital Home to Meredith's Magazines

In addition to gaining magazines such as Better Homes and Gardens, Parents and Family Circle, Media General will become the nation's third-largest TV broadcast group.

Sangui BioTech: Positive Outlook After Weak Fourth Quarter / Cost Cutting Initiated

According to preliminary, unaudited figures Sangui Biotech International, Inc.

Sangui BioTech International Files S-1 Registration Statement With The SEC

Sangui Biotech International, Inc. has filed a preliminary S-1 Registration Statement with the Securities and Exchange Commission.

Sangui BioTech International Secures Financial Framework Of $5 Million Over Three Years

Sangui Biotech International, Inc. has signed an agreement securing a financial framework of USD 5 million.

Sangui BioTech: Series Of Preclinical Trials Concluded Successfully

The research team embracing Sangui BioTech GmbH, the Excellence Cluster Cardio Pulmonary System (ECCPS) and TransMIT Gesellschaft für Technologietransfer mbH has now successfully concluded a series of preclinical...

SanguiBioTech: SastoMed Closes Contracts With Distribution Partners In Six Additional Markets In Eastern Europe

SastoMed GmbH has informed Sangui of having closed contracts for initiating distribution and sales of the Sangui developed dressing material Granulox in six Eastern European countries.

SanguiBioTech Yields Revenues Of Over USD31,000 In Q2 2015 According To Preliminary Figures

According to preliminary, unaudited figures Sangui Biotech International, Inc.

Sangui BioTech: Revenues Improved In The First Quarter Of The 2015 Financial Year

For the first quarter (as of September 30, 2014) of its 2015 financial year Sangui BioTech International, Inc.

Sangui Biotech: Preclinical Trials Demonstrate: Sangui Hemoglobin Preparation Improves Oxygen Supply Of Vital Organs

A possible success in treating septic shock has now been attained by the research team embracing SanguiBioTech GmbH, the Excellence Cluster Cardio Pulmonary System (ECCPS) and TransMIT Gesellschaft für ...

Sangui BioTech International Officially Approved As Trading On OTCQB

OTC Markets Group has officially informed Sangui Biotech International, Inc.

Sangui BioTech Yields Revenues Of Over USD70,000 In Q1 2015 According To Preliminary Figures

According to preliminary, unaudited figures Sangui BioTech International, Inc.

SanguiBioTech: Revenues Attain USD 133,000 In Financial Year 2014

For its financial year 2014 (ended June 30, 2014) Sangui BioTech International, Inc.